{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"limitationsAndCaveats":{"description":"Although E6201 exhibited an acceptable safety profile when administered at doses up to the MTD of 320 mg/m\\^2 IV twice weekly, insufficient efficacy was observed during the Phase 1 portion of the study. Thus, the Phase 2a portion was not initiated."},"pointOfContact":{"email":"linda.paradiso@spiritaoncology.com","organization":"Spirita Oncology, LLC","phone":"+1 (713) 898-8965","title":"Chief Development Officer"}}